Medical Oncology

, 30:735 | Cite as

The expression and prognosis of Emi1 and Skp2 in breast carcinoma: associated with PI3K/Akt pathway and cell proliferation

  • Xiaobing LiuEmail author
  • Hua Wang
  • Jing Ma
  • Junfei Xu
  • Chenyi Sheng
  • Shuyun Yang
  • Lingling Sun
  • Qichao NiEmail author
Original Paper


S-phase kinase protein 2 (Skp2) is oncogenic and overexpressed in human breast cancer. The objective of this study was to examine the effect of early mitotic inhibitor-1 (Emi1) over-expression on Skp2 expression and related signaling pathway in breast cancer. Immunohistochemical analysis was performed in 98 human breast carcinoma samples and the data were correlated with clinicopathologic features. Furthermore, Western blot analysis was performed for Emi1 and Skp2 in breast carcinoma samples and cell lines to evaluate their protein levels and molecular interaction. We found that the expression of Emi1 was positively related with Skp2 expression (P < 0.01) and Emi1 expression correlated significantly with histologic grade (P = 0.005), meanwhile Skp2 expression obtained similar results. Kaplan–Meier analysis revealed that survival curves of low versus high expressers of Emi1 and Skp2 showed a highly significant separation in human breast cancer (P < 0.01). While in vitro, following release of breast cancer cell lines from serum starvation, the expression of Emi1, Skp2, phosphor-Akt (p-Akt) was up-regulated, whereas p27Kip1 was down-regulated. Treatment of phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 could arrest cells growth and diminish Emi1 expression. These results suggested that Emi1’s anti-apoptotic and proliferative abilities appear to be triggered at least in part by the modulation of Skp2, combined Emi1 and Skp2 expressions, may be prognostic for patients with invasive breast carcinomas, which also associated with p-Akt and enabled p27kip1 degradation. Emi1 may serve as a potential therapeutic strategy aimed at PI3K for the management of breast cancer.


Emi1 Skp2 Breast cancer Prognosis PI3K/Akt 



Early mitotic inhibitor-1


S-phase kinase-associated protein 2


Anaphase-promoting complex/cyclosome


Phosphatidylinositol 3-kinase





This work was supported by the National Natural Scientific Foundation of China Grant (No. 30972937), Natural Scientific Foundation of Jiangsu Province Grant (No. H201017).

Conflict of interest

The authors declare that they have no conflict of interests.


  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMedGoogle Scholar
  2. 2.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  3. 3.
    Johnson DG, Walker CL. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 1999;39:295–312.CrossRefPubMedGoogle Scholar
  4. 4.
    Guardavaccaro D, Kudo Y, Boulaire J, et al. Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo. Dev Cell. 2003;4:799–812.CrossRefPubMedGoogle Scholar
  5. 5.
    Hsu JY, Reimann JD, Sorensen CS, et al. E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APC(Cdh1). Nat Cell Biol. 2002;4:358–66.CrossRefPubMedGoogle Scholar
  6. 6.
    Margottin-Goguet F, Hsu JY, Loktev A, et al. Prophase destruction of Emi1 by the SCF(betaTrCP/Slimb) ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase. Dev Cell. 2003;4:813–26.CrossRefPubMedGoogle Scholar
  7. 7.
    Reimann JD, Gardner BE, Margottin-Goguet F, Jackson PK. Emi1 regulates the anaphase-promoting complex by a different mechanism than Mad2 proteins. Genes Dev. 2001;15:3278–85.CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Miller JJ, Summers MK, Hansen DV, et al. Emi1 stably binds and inhibits the anaphase-promoting complex/cyclosome as a pseudosubstrate inhibitor. Genes Dev. 2006;20:2410–20.CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Gutgemann I, Lehman NL, Jackson PK, Longacre TA. Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma. Mod Pathol. 2008;21:445–54.CrossRefPubMedGoogle Scholar
  10. 10.
    Lehman NL, Tibshirani R, Hsu JY, et al. Oncogenic regulators and substrates of the anaphase promoting complex/cyclosome are frequently overexpressed in malignant tumors. Am J Pathol. 2007;170:1793–805.CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Schaner ME, Ross DT, Ciaravino G, et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell. 2003;14:4376–86.CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    Wang Q, Moyret-Lalle C, Couzon F, et al. Alterations of anaphase-promoting complex genes in human colon cancer cells. Oncogene. 2003;22:1486–90.CrossRefPubMedGoogle Scholar
  13. 13.
    Shapira M, Kakiashvili E, Rosenberg T, Hershko DD. The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells. Breast Cancer Res. 2006;8:R46.CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    Liu W, Asa SL, Fantus IG, et al. Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/akt-dependent and -independent pathways. Am J Pathol. 2002;160:511–9.CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Gstaiger M, Jordan R, Lim M, et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA. 2001;98:5043–8.CrossRefPubMedCentralPubMedGoogle Scholar
  16. 16.
    Masuda TA, Inoue H, Sonoda H, et al. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res. 2002;62:3819–25.PubMedGoogle Scholar
  17. 17.
    Signoretti S, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, Monti F, Loda M, Pagano M. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest. 2002;110:633–41.CrossRefPubMedCentralPubMedGoogle Scholar
  18. 18.
    Yang G, Ayala G, De Marzo A, et al. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res. 2002;8:3419–26.PubMedGoogle Scholar
  19. 19.
    Traub F, Mengel M, Luck HJ, et al. Prognostic impact of Skp2 and p27 in human breast cancer. Breast Cancer Res Treat. 2006;99:185–91.CrossRefPubMedGoogle Scholar
  20. 20.
    Zheng WQ, Zheng JM, Ma R, Meng FF, Ni CR. Relationship between levels of Skp2 and P27 in breast carcinomas and possible role of Skp2 as targeted therapy. Steroids. 2005;70:770–4.CrossRefPubMedGoogle Scholar
  21. 21.
    Gao D, Inuzuka H, Tseng A, et al. Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction. Nat Cell Biol. 2009;11:397–408.CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Lin HK, Wang G, Chen Z, et al. Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol. 2009;11:420–32.CrossRefPubMedCentralPubMedGoogle Scholar
  23. 23.
    Gesbert F, Sellers WR, Signoretti S, et al. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J Biol Chem. 2000;275:39223–30.CrossRefPubMedGoogle Scholar
  24. 24.
    Murillo H, Huang H, Schmidt LJ, et al. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology. 2001;142:4795–805.CrossRefPubMedGoogle Scholar
  25. 25.
    Pene F, Claessens YE, Muller O, et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene. 2002;21:6587–97.CrossRefPubMedGoogle Scholar
  26. 26.
    Liu J, Wei XL, Huang WH, Chen CF, Bai JW, Zhang GJ. Cytoplasmic Skp2 expression is associated with p-Akt1 and predicts poor prognosis in human breast carcinomas. PLoS ONE. 2012;7:e52675.CrossRefPubMedCentralPubMedGoogle Scholar
  27. 27.
    Remmele W, Muhlfait V, Keul HG. Estimation of the proliferative activity of human breast cancer tissue by means of the Ki-67 and MIB-1 antibodies–comparative studies on frozen and paraffin sections. Virchows Arch. 1995;426:435–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Hansen DV, Loktev AV, Ban KH, Jackson PK. Plk1 regulates activation of the anaphase promoting complex by phosphorylating and triggering SCFbetaTrCP-dependent destruction of the APC Inhibitor Emi1. Mol Biol Cell. 2004;15:5623–34.CrossRefPubMedCentralPubMedGoogle Scholar
  29. 29.
    Machida YJ, Dutta A. The APC/C inhibitor, Emi1, is essential for prevention of rereplication. Genes Dev. 2007;21:184–94.CrossRefPubMedCentralPubMedGoogle Scholar
  30. 30.
    Ewerth D, Schmidts A, Kuegelgen B, Wider D, Schuler J, Engelhardt M, Wasch R. Dissecting stem cell proliferation and differentiation in association with the central cell cycle regulator APC/CCdh1. Blood (ASH Annual Meeting Abstracts). 2012;120:Abstract 1236.Google Scholar
  31. 31.
    Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med. 1997;3:227–30.CrossRefPubMedGoogle Scholar
  32. 32.
    Mori M, Mimori K, Shiraishi T, et al. p27 expression and gastric carcinoma. Nat Med. 1997;3:593.CrossRefPubMedGoogle Scholar
  33. 33.
    Chiarle R, Pagano M, Inghirami G. The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Res. 2001;3:91–4.CrossRefPubMedCentralPubMedGoogle Scholar
  34. 34.
    Vazquez F, Sellers WR. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta. 2000;1470:M21–35.PubMedGoogle Scholar
  35. 35.
    Burgering BM, Medema RH. Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. J Leukoc Biol. 2003;73:689–701.CrossRefPubMedGoogle Scholar
  36. 36.
    Plas DR, Thompson CB. Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J Biol Chem. 2003;278:12361–6.CrossRefPubMedGoogle Scholar
  37. 37.
    Kulik G, Carson JP, Vomastek T, et al. Tumor necrosis factor alpha induces BID cleavage and bypasses antiapoptotic signals in prostate cancer LNCaP cells. Cancer Res. 2001;61:2713–9.PubMedGoogle Scholar
  38. 38.
    Izuishi K, Kato K, Ogura T, et al. Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy. Cancer Res. 2000;60:6201–7.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Xiaobing Liu
    • 1
    Email author
  • Hua Wang
    • 1
  • Jing Ma
    • 1
  • Junfei Xu
    • 1
  • Chenyi Sheng
    • 1
  • Shuyun Yang
    • 2
  • Lingling Sun
    • 1
  • Qichao Ni
    • 1
    Email author
  1. 1.Department of General SurgeryAffiliated Hospital of Nantong UniversityNantongPeople’s Republic of China
  2. 2.Department of Pathology, Affiliated Cancer Hospital of Nantong UniversityMedical College of Nantong UniversityNantongPeople’s Republic of China

Personalised recommendations